-
公开(公告)号：US20170210724A1
公开(公告)日：2017-07-27
申请号：US15481852
申请日：2017-04-07
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Xingyu Lin , Jason Burch
IPC: C07D401/10 , C07D401/14 , C07D491/107 , C07D409/14 , C07D405/14 , C07D495/04 , C07D495/06 , C07D471/04 , C07D487/04 , C07D413/10 , C07D403/10 , C07D405/10 , C07D417/14 , C07D491/048 , C07D413/14
CPC classification number: C07D401/10 , A61K31/395 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/10 , C07D405/14 , C07D409/14 , C07D413/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/107 , C07D495/04 , C07D495/06
Abstract: The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20170145034A1
公开(公告)日：2017-05-25
申请号：US15425698
申请日：2017-02-06
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D513/04 , C07D401/14 , C07D491/052 , C07D471/04 , C07D413/10 , C07D491/048 , C07D403/14 , C07D413/14 , C07D495/04 , C07D487/04 , C07D417/10 , C07D403/10 , C07D401/10
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20160096850A9
公开(公告)日：2016-04-07
申请号：US14466153
申请日：2014-08-22
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D513/04 , C07D471/04 , C07D403/10 , C07D401/14 , C07D413/10 , C07D491/052 , C07D487/04 , C07D401/10
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20220204498A1
公开(公告)日：2022-06-30
申请号：US17404568
申请日：2021-08-17
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Joachim Rudolph , Yao Wu , Guosheng Wu
IPC: C07D471/04
Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof useful in the treatment of IRE1-related diseases and disorders described herein.
-
Patent Agency Ranking
公开(公告)号：US10800780B2
公开(公告)日：2020-10-13
申请号：US16065397
申请日：2016-12-23
Applicant: Genentech, Inc. , NewLink Genetics Corporation
Inventor： Xingyu Lin , Po-wai Yuen , Rohan Mendonca , Brendan Parr , Richard Pastor , Zhonghua Pei , Lewis Gazzard , Firoz Jaipuri , Sanjeev Kumar , Xiaokai Li , Roheeth Pavana , Hima Potturi , Venkata Velvadapu , Jesse Waldo , Zuhui Zhang , Guosheng Wu , Benjamin Douglas Sellers
IPC: A61K31/4188 , A61K31/407 , A61K31/4035 , C07D487/04 , C07D519/00 , A61P35/00 , A61K45/06 , A61K38/16
Abstract: Presently provided are inhibitors of cellularly expressed TDO2 and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2, 3 dioxygenase; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
-
公开(公告)号：US10065970B2
公开(公告)日：2018-09-04
申请号：US15258175
申请日：2016-09-07
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Keira Garland , Emily Hanan , Hans Purkey , Steven T. Staben , Robert Andrew Heald , Jamie Knight , Calum Macleod , Aijun Lu , Guosheng Wu , Siew Kuen Yeap
IPC: C07D498/04 , A61K31/553 , A61K31/5383 , A61K31/498 , A61K31/4439 , A61K31/428 , A61K31/423 , A61K31/4196 , C07D491/044 , A61K45/06 , C07D519/00
CPC classification number: C07D498/04 , A61K31/4188 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/498 , A61K31/5365 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D491/044 , C07D498/06 , C07D519/00
Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
-
公开(公告)号：US20180162873A9
公开(公告)日：2018-06-14
申请号：US15258175
申请日：2016-09-07
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Keira Garland , Emily Hanan , Hans Purkey , Steven T. Staben , Robert Andrew Heald , Jamie Knight , Calum Macleod , Aijun Lu , Guosheng Wu , Siew Kuen Yeap
IPC: C07D498/04 , A61K31/553 , A61K31/5383 , A61K31/498 , A61K31/4439 , A61K31/428 , A61K31/423 , A61K31/4196 , C07D491/044 , A61K45/06 , C07D519/00
CPC classification number: C07D498/04 , A61K31/4188 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/498 , A61K31/5365 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D491/044 , C07D498/06 , C07D519/00
Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
-
公开(公告)号：US09605005B2
公开(公告)日：2017-03-28
申请号：US15074100
申请日：2016-03-18
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Jason Burch
IPC: C07D401/00 , C07D513/04 , C07D401/14 , C07D413/14 , C07D401/10 , C07D403/10 , C07D403/14 , C07D413/10 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
CPC classification number: C07D513/04 , C07D401/10 , C07D401/14 , C07D403/10 , C07D403/14 , C07D413/10 , C07D413/14 , C07D417/10 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/052 , C07D495/04
Abstract: The invention relates to compounds of Formula (0): wherein Q, A1-A8, R4 and R5 and each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
-
公开(公告)号：US20150057260A1
公开(公告)日：2015-02-26
申请号：US14466176
申请日：2014-08-22
Applicant: Genentech, Inc.
Inventor： Nicole Blaquiere , Georgette Castanedo , Jianwen A. Feng , Baihua Hu , Steven Staben , Po-wai Yuen , Guosheng Wu , Xingyu Lin , Jason Burch
IPC: C07D495/04 , C07D403/10 , C07D405/14 , C07D409/14 , C07D491/107 , C07D403/14 , C07D401/10
CPC classification number: C07D401/10 , A61K31/395 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/10 , C07D405/14 , C07D409/14 , C07D413/10 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D491/048 , C07D491/107 , C07D495/04 , C07D495/06
Abstract: The invention relates to compounds of Formula (0): wherein A1-A8, R4 and R5 each has the meaning as described herein. Compounds of Formula (0) and pharmaceutical compositions thereof are useful in the treatment of diseases and disorders in which undesired or over-activation of NF-kB signaling is observed.
Abstract translation: 本发明涉及式（O）的化合物：其中A1-A8，R4和R5各自具有如本文所述的含义。 式（0）的化合物及其药物组合物可用于治疗其中观察到NF-kB信号传导的不期望或过度活化的疾病和病症。
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.041 seconds)
